Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
November 2015
-
Media ReleaseNovartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritisCosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and…
-
Media ReleaseNovartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patientsNew x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Media ReleaseNew two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitisA sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
October 2015
-
Media ReleaseNovartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritisCosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
-
Media ReleaseNovartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 yearsLate-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a proposed biosimilar etanerceptEtanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
June 2015
-
Media ReleaseNovartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patientsIn the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
-
Media ReleaseNovartis highlights strong innovation momentum at its second Meet Novartis Management investor dayStrong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
-
Media ReleaseNovartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patientsNew analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page